September 7, 2026

Company name: SanBio Co., Ltd.
(Code: 4592 TSE Growth)
Name of Representative: Keita Mori, Representative Director and President
For inquiries, contact: Yoshihiro Kakutani, Corporate Officer of Management Administration
(Phone: +81-(0)3-6264-3481)

[Delayed] Notice Regarding Integration of AKUUGO® Manufacturing Operations in Japan Following Closure of Minaris' U.S. Facility

SanBio Co., Ltd. (head office: Tokyo, Japan; Representative Director and President: Keita Mori; hereinafter the "Company") hereby announces that it has received notification from Minaris Advanced Therapies LLC ("Minaris"), a contract manufacturer responsible for a portion of the manufacturing process for AKUUGO® Suspension for Intracranial Implantation (INN: vandefitemcel; "AKUUGO®"), that Minaris will close its Mountain View facility in California, U.S.

1. Overview of the notification and the Company's response

On August 31, 2026, the Company received notification from Minaris that it plans to close its Mountain View facility on September 1, 2026, and terminate the lease for the facility on October 31, 2026.

The closure is part of Minaris' restructuring of manufacturing operations. The Company will take this opportunity to work with Minaris Advanced Therapies Co., Ltd. ("Minaris Japan") to transfer the upstream processes for AKUUGO® manufacturing performed at the Mountain View facility to Minaris Japan's Yokohama facility, which currently handles the downstream processes. Through this transfer, the Company aims to establish an integrated manufacturing system in Japan covering the entire process from upstream through downstream manufacturing.

2. Integration of manufacturing processes in Japan and product supply

By integrating the manufacturing processes for AKUUGO® in Japan, the Company aims to enhance coordination in manufacturing management and improve production stability and efficiency. Following the transfer of manufacturing operations to Minaris Japan's Yokohama facility and approval of the necessary partial changes to approved matters, the Company expects to begin shipments of AKUUGO® manufactured entirely at the facility.

The Company has already secured inventory of AKUUGO® for domestic sales and other needs and expects this inventory to be sufficient to meet demand until the aforementioned shipments begin. Accordingly, the Company does not expect this matter to have a material impact on product supply to patients or its sales. The Company is also diversifying its contract manufacturing network to further strengthen the stable supply of AKUUGO®. Specifically, the Company has entered into a trial manufacturing agreement with JCR Pharmaceuticals Co., Ltd. aimed at commercial production of AKUUGO® and is establishing a manufacturing system at JCR Pharmaceuticals. Through the integration of manufacturing processes at Minaris Japan's Yokohama facility and the use of multiple contract manufacturers, including JCR Pharmaceuticals, the Company aims to further strengthen the stable supply of AKUUGO® and increase production capacity. In doing so, the Company will establish a manufacturing system capable of meeting the anticipated future increase in demand associated with its previously announced U.S. expansion and extension of the indication to include ischemic stroke.

The Company does not expect this matter to have a material impact on its financial performance for the current fiscal year. The Company will promptly announce any matters requiring disclosure as they arise.